8/2/2011 3:05:56 PM
August 2, 2011 -- BGI, the giant genomics institute located in Shenzhen, and GT Life Sciences of San Diego have published their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line in Nature Biotechnology. Over 70% of the recombinant therapeutic proteins sold today are manufactured using mammalian cells, primarily CHO cell lines. GT Life Sciences uses a metabolic modeling platform to design new products and processes for the life sciences field. It says a better understanding of the genome will speed development of new recombinant protein therapies. More details....
comments powered by